Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


ChildVaxView


Facebook
        Twitter
        LinkedIn
        Syndicate





Supplementary figures and table for Vaccination Coverage by Age 24 Months Among Children Born in 2016 and 2017 – National Immunization Survey-Child, United States, 2017-2019										Related Pages
										On This Page
			Supplementary Figure 1Supplementary Figure 2Supplementary Table 1
FIGURE 1. Estimated vaccination coverage by age 24 months,* by birth year† – National Immunization Survey-Child, United States, 2012-2019
FIGURE 1. Estimated vaccination coverage by age 24 months,* by birth year† – National Immunization Survey-Child, United States, 2012-2019**Abbreviations:** DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.
* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).
† Children born in 2011 are included in survey years 2012, 2013, and 2014; children born in 2012 are included in survey years 2013, 2014, and 2015; children born in 2013 are included in survey years 2014, 2015, and 2016, children born in 2014 are included in survey years 2015, 2016, and 2017; children born in 2015 are included in survey years 2016, 2017, and 2018; children born in 2016 are included in survey years 2017, 2018, and 2019; children born in 2017 are included in survey years 2018 and 2019 (data from survey year 2020 are not yet available).
§Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.
¶ Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.
** Hib full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.
†† One dose HepB administered from birth through age 3 days.
§§ Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). (If any dose in the series is either RotaTeq or unknown, default to the 3-dose series.) The maximum age for the final rotavirus dose is 8 months, 0 days.
¶¶ Doses must be at least 24 days apart (four weeks with a four-day grace period); doses could have been received during two influenza seasons.
*** The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.
FIGURE 2. Estimated percentage of children who received no vaccinations by age 24 months,* by birth year† – National Immunization Survey-Child, United States, 2012-2019
FIGURE 2. Estimated percentage of children who received no vaccinations by age 24 months,* by birth year† – National Immunization Survey-Child, United States, 2012-2019**Abbreviations:**CI = confidence interval****
* Kaplan-Meier techniques are used to calculate estimates by age 24 months.
† Children born in 2011 are included in survey years 2012, 2013, and 2014; children born in 2012 are included in survey years 2013, 2014, and 2015; children born in 2013 are included in survey years 2014, 2015, and 2016, children born in 2014 are included in survey years 2015, 2016, and 2017; children born in 2015 are included in survey years 2016, 2017, and 2018; children born in 2016 are included in survey years 2017, 2018, and 2019; children born in 2017 are included in survey years 2018 and 2019 (data from survey year 2020 are not yet available). Estimated linear relationship between year of birth and vaccination status, based on weighted linear regression analysis using the inverse of the estimated variance of each point estimate to construct the weights. Observed percent unvaccinated (95% confidence interval):  2011 0.9 (0.6-1.3); 2012 1.1 (0.8-1.4); 2013 1.1 (0.8-1.4), 2014 1.2 (1.0-1.5); 2015 1.3 (1.1-1.6); 2016 1.5 (1.2-1.8); 2017 (preliminary) 0.9 (0.7-1.1). Estimated percentage point change per year: 0.034 (-0.070-0.138).
TABLE. Vaccination coverage estimates for bridging cohort,* National Immunization Survey-Child, United States, 2018-2019
**Abbreviations**: DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine, SE = standard error; VAR = varicella vaccine.
Vaccination coverage estimates for bridging cohort,* National Immunization Survey-Child, United States, 2018-2019
Survey Year 2018
Survey Year 2019
Difference
(2019 – 2018)
P-value for Test of Difference=0Vaccine
Estimate
SE
Estimate
SE
Estimate
SE≥3 DTaP by 19 months
93.2
0.50
91.8
0.63
-1.4
0.81
0.085≥4 DTaP by 19 months
69.9
1.13
72.2
1.00
2.3
1.51
0.120≥3 Poliovirus by 19 months
92.2
0.53
90.4
0.71
-1.8
0.89
0.041≥1 MMR by 19 months
87.7
0.76
87.4
0.79
-0.3
1.10
0.802Hib primary series† by 19 months
92.0
0.66
91.3
0.65
-0.6
0.93
0.489Hib full series† by 19 months
74.5
1.06
75.3
0.96
0.8
1.43
0.583HepB birth dose§
76.6
0.92
75.5
1.02
-1.1
1.38
0.412≥3 HepB by 19 months
91.0
0.58
89.8
0.75
-1.1
0.95
0.229≥1 VAR by 19 months
86.9
0.79
86.1
0.81
-0.8
1.13
0.500≥3 PCV by 19 months
91.2
0.69
90.7
0.66
-0.5
0.95
0.613≥4 PCV by 19 months
77.4
1.06
77.8
0.95
0.4
1.42
0.772≥1 HepA by 19 months
81.2
0.92
81.5
0.87
0.3
1.27
0.800≥2 HepA by 19 months
27.2
0.98
25.9
0.99
-1.3
1.40
0.347Rotavirus¶ by 19 months
75.7
1.08
76.3
0.95
0.6
1.44
0.675≥2 Influenza** by 19 months
55.3
1.12
53.6
1.11
-1.6
1.58
0.297Combined 7-vaccine series†† by 19 months
60.3
1.16
62.4
1.09
2.1
1.59
0.190No vaccinations
1.2
0.17
1.0
0.13
-0.2
0.21
0.285* The bridging birth cohort includes children born from January 2016 to May 2017 who were included in the 2018 National Immunization Survey-Child and children born from January 2016 to May 2017 who were included in the 2019 National Immunization Survey-Child.
†Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.
§One dose HepB administered from birth through age 3 days.
¶Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). (If any dose in the series is either RotaTeq or unknown, default to 3-dose series.) The maximum age for the final rotavirus dose is 8 months, 0 days.
** Doses must be at least 24 days apart (four weeks with a four-day grace period); doses could have been received during two influenza seasons.
†† The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.
Top of Page
							
					
						Page last reviewed:  September 28, 2020					Content source: 	National Center for Immunization and Respiratory Diseases ChildVaxView Home
ChildVaxView Interactive!
Publications and Resources
Data Source
Objectives, Targets, and Indicators
For Specific Groupsplus icon
Health Care Professionals
Parents
NIS-Child Survey Participants
Media SchoolVaxView
TeenVaxView
AdultVaxView
FluVaxView
COVIDVaxView
Association of Immunization Managers (AIM)external icon


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue